Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCLAIM-CX-072 dose-finding and proof-of-concept study
NL-OMON47426Phase 2Completed
- Sponsor
- CytomX
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pacmilimab in Nonhematologic neoplasms, lymphoma, melanoma and 8 more (8 arms), sponsored by CytomX. Primary endpoints: Safety and tolerability, Maximum tolerated dose and dose-limiting toxicities and 2 more. Started Oct 2017; status: completed.
02
Drugs
pacmilimab
03
Conditions
Nonhematologic neoplasmslymphomamelanomaMalignant Fibrous Histiocytoma (MFH)small bowel adenocarcinoma (SBA)
Beyond the preview
Go deeper on NL-OMON47426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47426.